Bill Sponsor
Senate Bill 586
117th Congress(2021-2022)
NOPAIN Act
Introduced
Introduced
Introduced in Senate on Mar 4, 2021
Overview
Text
Introduced
Mar 4, 2021
Latest Action
Mar 4, 2021
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
586
Congress
117
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Republican
West Virginia
Democrat
Arizona
Republican
Arkansas
Democrat
Connecticut
Democrat
Delaware
Democrat
Delaware
Democrat
Georgia
Democrat
Illinois
Republican
Indiana
Republican
Louisiana
Republican
Louisiana
Democrat
Michigan
Democrat
Minnesota
Democrat
Minnesota
Republican
Mississippi
Republican
Missouri
Democrat
Montana
Republican
Nebraska
Democrat
New Hampshire
Republican
North Carolina
Republican
North Dakota
Republican
Oklahoma
Democrat
Pennsylvania
Democrat
Rhode Island
Democrat
Rhode Island
Republican
South Carolina
Republican
South Dakota
Democrat
Virginia
Democrat
Virginia
Democrat
West Virginia
Democrat
Wisconsin
Senate Votes (0)
House Votes (0)
No Senate votes have been held for this bill.
Summary

Non-Opioids Prevent Addiction In the Nation Act or the NOPAIN Act

This bill temporarily establishes separate payments for certain non-opioid treatments under the Medicare prospective payment system for hospital outpatient department services and the payment system for ambulatory surgical center services. The bill applies to pain management treatments that are able to replace or reduce opioid consumption, as shown through clinical trials or data.

Text (1)
Actions (2)
03/04/2021
Read twice and referred to the Committee on Finance.
03/04/2021
Introduced in Senate
Public Record
Record Updated
Jan 11, 2023 1:47:48 PM